Takeda’s Zika virus vaccine candidate progresses into Phase 1 clinical trial
by Press Release from Outbreak News Today on (#398Y3)
Takeda Pharmaceuticals today announced that its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate (TAK-426) has progressed into a Phase 1 clinical trial, approximately 15 months after Takeda received a contract to develop a Zika vaccine from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced ["]
The post Takeda's Zika virus vaccine candidate progresses into Phase 1 clinical trial appeared first on Outbreak News Today.